FL-WELLVII
3.1.2023 14:01:43 CET | Business Wire | Press release
Wellvii, manufacturer of connected smart devices for health and wellbeing, today announced a partnership with Care Daily, a software technology company with AI-based Caregiver services for senior care, to bring integrated solutions for aging-in-place experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005097/en/
myWellvii Platform (Photo: Business Wire)
Patients are now, more than ever, extremely receptive to personal health management solutions. The consumerization and democratization of healthcare gained significant momentum prior to the pandemic and COVID-19 has further accelerated this trend. The partnership between Wellvii and Care Daily will let users take control of their wellbeing with self-monitoring and give them an enhanced view into their overall health.
“The core devices of the myWellvii Platform; the Wellvii MVS1, Wellvii Go wearable, and Wellvii Weight scale in conjunction with the Care Daily’s AI and IoT platform will enable a comprehensive solution for families to measure their health and wellness and improve their well-being.” Mark Khachaturian, PhD CEO of Wellvii.
“Care Daily has commercialized the most advanced AI Caregiver intelligence which, until today, has primarily captured data from ambient sensors in homes to learn lifestyle patterns, trends, and activities of daily living,” said David Moss, CEO of Care Daily. “Integrating Wellvii’s core devices with our AI Caregiver services unifies the lifestyle trends in the home with the biometric trends from the resident’s body, providing an unparalleled understanding of how this person is truly doing. Senior care solutions providers are excited about the opportunity to bring these differentiated services to market under their own brands.”
Both companies are in discussions with major providers to trial the combined technology in homes. Top use cases include senior care and chronic care management.
About Wellvii
Wellvii enables the delivery of healthcare at any address through its all in one comprehensive, clinically validated, connected device that measures 11 vital parameters from the finger, including an oscillometric blood pressure finger cuff. Wellvii also introduces a comprehensive wellness scoring system including the first at-home “stress test” using its proprietary fitness challenge. For more information about the myWellvii platform, click here.
1The Wellvii MVS is not a medical device and cannot be used for clinical applications in the USA. The Wellvii VitalDetect has CE Mark clearance as a Class IIa medical device in Europe. For more information on the Wellvii VitalDetect for Europe, click here. Wellvii has 60 patents issued (57 US, 2 UK, 1 EU).
Follow Wellvii on Twitter, LinkedIn, Instagram, and Facebook.
To directly contact Wellvii: info@wellvii.com.
About Care Daily
Care Daily is the only white-label home health AI and IoT SaaS that deeply personalizes the delivery of senior care through large brands. Care Daily is backed by the NIA, and the company’s award-winning AI Caregiver software intelligence is the first to achieve scientific validation for senior care assistive services in homes. Care Daily’s AI Caregiver personality and services are uniquely configurable by partners for maximum differentiation against other brands and solutions providers. The intelligence detects falls in real-time, uncovers hidden health problems, and brings families and professional caregivers together to care for seniors. Care Daily’s white-labeled solutions are utilized by some of the largest brands to quickly deploy and continually enhance personalized healthcare services for seniors in homes and communities. To learn more, visit www.CareDaily.ai or connect with us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005097/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom